Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.64 |
| ▸ | ESRRB | O95718 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESRRG | P62508 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383139 | 1.00 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2383143 | 1.00 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL8170341 | 0.88 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2384250 | 0.88 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2380967 | 0.88 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2383359 | 0.85 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL8158974 | 0.85 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL8170008 | 0.85 | ESRRA (1.00) | ESRRACYP3A4ESRRBESR1ESRRG | |
| SCHEMBL4366323 | 0.85 | ESRRA (0.86) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2383361 | 0.85 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | JANSSEN PHARAMCEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | JANSSEN PHARAMCEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-7846953-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-07 | — | — | US | disclosed |
| US-7846953-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-07 | — | — | US | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | ESR2, ESRRA, ESRRB | ESRRA 2/4885CYP3A4 1190/4885PIM1 1065/4885 |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885CYP3A4 1174/4885PIM1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.